Treatment of Vasomotor Symptoms

• US 20110136825A1
• Filed: 09/11/2008
• Published: 06/09/2011
• Est. Priority Date: 09/12/2007
• Status: Abandoned Application

• Current Assignee: Sprout Pharmaceuticals, Inc. (Sprout2, Inc.)
• Original Assignee: Boehringer Ingelheim International GmbH (C.H. Boehringer Sohn AG & Co. KG)
• Inventors: Verbeek, Annelies, Hanes, Vladimir
• Application Number:
  US12/675,231
• Publication Number:
  US 20110136825A1
• Time in Patent Office: Days
• US Class Current: 514/254.06
• CPC Class Codes: A61K 31/496 Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• CPC Class Codes: A61P 15/12 for climacteric disorders

Abstract

The invention relates to a method for the treatment of vasomotor symptoms comprising the administration of a therapeutically effective amount of flibanserin.

Claims

1. A method for the treatment of vasomotor symptoms comprising the administration of a therapeutically effective amount of flibanserin, or a pharmacologically acceptable acid addition salt, hydrate, or solvate, thereof.

2. The method according to claim 1, wherein the vasomotor symptoms are vasomotor symptoms associated with menopause.

3. The method according to claim 1, wherein the vasomotor symptoms are vasomotor symptoms associated with surgically induced menopause.

4. The method according to claim 1, wherein the vasomotor symptoms are vasomotor symptoms associated with iatrogenic induced menopause.

5. The method according to claim 1, wherein the vasomotor symptoms are vasomotor symptoms associated with the use of medication, radiation, or chemotherapeutic agents.

6. The method according to claim 1, wherein the vasomotor symptoms are selected from the group consisting of hot flashes, night sweats, moodswings, and irritability.

7. The method according to claim 1, wherein the vasomotor symptoms are moderate to severe vasomotor symptoms associated with a natural or iatrogenic hypogonadal state in men.

8. The method according to claim 7, wherein the vasomotor symptoms are vasomotor symptoms associated with the use of medication, radiation, or chemotherapeutic agents.

9. The method according to claim 7, wherein the vasomotor symptoms are hot flashes in men.

10. The method according to any one of the claims 1 to 9 or 13 or 14, wherein the flibanserin is administered as a pharmaceutically acceptable acid addition salt selected from the salts formed by succinic acid, hydrobromic acid, acetic acid, fumaric acid, maleic acid, methanesulphonic acid, lactic acid, phosphoric acid, hydrochloric acid, sulphuric acid, tartaric acid, citric acid, and mixtures thereof.

11. The method according one of the claims 1 to 9 or 13 or 14, wherein the flibanserin is administered as flibanserin polymorph A.

12. The method according one of the claims 1 to 9 or 13 or 14, wherein the flibanserin is applied in a dosis range between 0.1 to 400 mg per day.

13. The method according to claim 4, wherein the vasomotor symptoms are vasomotor symptoms associated with the use of medication, radiation, or chemotherapeutic agents.

14. The method according to claim 8, wherein the vasomotor symptoms are hot flashes in men.